Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | ALK |
Variant | G1202K |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ALK G1202K lies within the protein kinase domain of the Alk protein (UniProt.org). G1202K has been identified in the scientific literature (PMID: 33790576), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Nov 2023). |
Associated Drug Resistance | |
Category Variants Paths |
ALK mutant ALK G1202X ALK G1202K |
Transcript | NM_004304.5 |
gDNA | chr2:g.29220746_29220747delGGinsAA |
cDNA | c.3604_3605delGGinsAA |
Protein | p.G1202K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004304.4 | chr2:g.29220746_29220747delGGinsAA | c.3604_3605delGGinsAA | p.G1202K | RefSeq | GRCh38/hg38 |
NM_004304.5 | chr2:g.29220746_29220747delGGinsAA | c.3604_3605delGGinsAA | p.G1202K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK G1202K | lung adenocarcinoma | predicted - sensitive | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, fourth-line Lorbrena (lorlatinib) treatment resulted in symptom improvement and response in lung disease with a progression-free survival lasting 4 months in an EML4-ALK positive a patient with lung adenocarcinoma patient harboring EML4-ALK and an acquired ALK G1202K, who had previously progressed on Xalkori (crizotinib) and Alecensa (alectinib) treatment (PMID: 33790576). | 33790576 |